Developer docs
API playgroundTry for free, no card

Search company profiles

Creyon Bio

Full company profile

uuid0000p17

Namestring
Creyon Bio
Legal namestring
Creyon Bio
Websiteurl
creyonbio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Creyon Bio is a privately held drug development company engineering oligonucleotide-based medicines (OBMs) for immunology, central nervous system (CNS), and neuromuscular diseases. The company combines two proprietary technology pillars: an aptamer-based delivery platform—anchored by a transferrin receptor (TfR) aptamer with validated preclinical proof-of-concept for crossing the blood-brain barrier—and the NuclelQ™ AI-powered nucleic acid engineering platform, which leverages proprietary pharmacology datasets and AI/ML predictive tools to design safe and active nucleic acid candidates. Creyon has three active wholly-owned programs, including a first-in-class splice-switching oligonucleotide therapy for late-onset Pompe disease and a CNS program enabled by BBB-crossing delivery; the platform is also being extended to direct lipid nanoparticles (LNPs) to immune and other cell types beyond oligonucleotides.

The company operates a licensing and partnership-driven business model rather than selling products directly. Revenue mechanics consist of upfront payments, development milestones, and royalties on partnered programs, anchored by a strategic partnership with Eli Lilly announced in 2025 valued at up to $1 billion for oligonucleotide therapeutics. Creyon is headquartered in San Diego, California with research operations in Research Triangle Park, North Carolina, and was launched in March 2022 with over $40 million in combined Seed and Series A funding co-led by DCVC Bio and Lux Capital. Customer base consists of large pharmaceutical partners rather than end patients or providers, with Eli Lilly named as the primary disclosed enterprise customer.

Short descriptiontext

Creyon Bio is a private drug development company engineering oligonucleotide-based medicines (OBMs) using aptamer delivery technology and its AI-powered NuclelQ platform for immunology, CNS, and neuromuscular diseases, generating revenue through pharmaceutical partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oligonucleotide-based medicines, RNA drug development, aptamer delivery technology, nucleic acid engineering, targeted RNA therapies
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNA-based Drug Development
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1RNA-based Drug Development & Licensing
TypeLicensing Royalties
Description

Creyon Bio is developing RNA-based medicines (OBMs) for treatment of immunology, CNS, and neuromuscular diseases. Revenue generation through licensing deals and eventual product commercialization for common and rare diseases.

hubs.li
2Strategic Partnership Deals
TypeLicensing Royalties
Description

Revenue through pharmaceutical partnerships such as the up to $1 billion deal with Eli Lilly for oligonucleotide therapeutics development and commercialization.

klover.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1NuclelQ™
Description

AI-Powered Nucleic Acid Engineering Platform that enables de-risked design of safe and active nucleic acid therapies using proprietary pharmacology datasets and AI/ML predictive tools.

creyon.com
Core offering1 text field

Creyon Bio is a drug development company engineering RNA-based medicines (Oligonucleotide-Based Medicines, or OBMs) for immunology, central nervous system (CNS), and neuromuscular diseases. Its approach combines the NuclelQ™ AI-powered nucleic acid engineering platform with proprietary aptamer-based delivery technology that targets specific cell types and can cross the blood-brain barrier, enabling tissue-specific delivery of siRNA and antisense oligonucleotides.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Creyon Bio is a drug development company offering a platform-plus-technology approach to RNA-based medicine design. The core offering is the NuclelQ™ AI-Powered Nucleic Acid Engineering Platform, which uses proprietary pharmacology datasets and machine learning to design nucleic acid therapies. This platform is combined with the company's Aptamer Delivery Technology for cell-specific targeting, including the Transferrin Receptor (TfR) Aptamer for blood-brain barrier crossing. The company engineers Oligonucleotide-Based Medicines (OBMs) as precision drugs for immunology, CNS, and neuromuscular diseases. Creyon has three active wholly-owned products in its pipeline, including a late-onset Pompe disease therapy and a CNS program. The platform can direct both aptamers and lipid nanoparticles (LNPs) to immune and other cell types.

Product and service3 records
1Late-Onset Pompe Disease Therapy
CategoryOligonucleotide therapeutic candidate
Description

First-in-class splice-switching oligonucleotide therapy leveraging the TfR aptamer for targeted muscle delivery in late-onset Pompe disease; intended to restore endogenous acid alpha-glucosidase (GAA) production and sustain glycogen reduction. Developed by Creyon Bio as a wholly-owned drug candidate for partnership-based clinical advancement.

2CNS Program (TfR Aptamer-Mediated Delivery)
CategoryOligonucleotide therapeutic candidate
Description

Wholly-owned CNS pipeline program using the transferrin receptor (TfR) aptamer to shuttle siRNA and antisense oligonucleotides across the blood-brain barrier to disease-relevant targets in the brain. Preclinical proof-of-concept demonstrated; intended to support a broad set of CNS indications.

3Immunology Program (T and B Cell-Targeted OBMs)
CategoryOligonucleotide therapeutic candidate
Description

Wholly-owned immunology pipeline of OBMs designed for precise delivery of therapeutic payloads to T and B cells using proprietary aptamers, intended to modulate immune pathways and treat immune-driven diseases.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Eli Lilly partnership for oligonucleotide therapeutics worth up to $1 billion, including development milestones and royalties. Part of Lilly's broader AI-driven pharmaceutical strategy combining high-stakes discovery partnerships with pragmatic operational AI deployment. Creyon Bio contributes differentiated RNA drug design capabilities using its aptamer delivery platform and NuclelQ AI technology.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dyne develops targeted oligonucleotide therapies (siRNA, ASO) for serious muscle diseases (DM1, DMD, FSHD, Pompe) using its FORCE antibody fragment-targeted platform. Direct peer given shared focus on muscle-targeted nucleic acid delivery and overlap in Pompe disease, though Dyne uses antibody fragments rather than aptamer-based targeting.

2Avidity Biosciences
TypeDirect peer
Description

Avidity develops antibody-oligonucleotide conjugates (AOCs) for muscle and CNS diseases including DM1, DMD, FSHD, and rare metabolic disorders. Direct peer due to nearly identical therapeutic-area focus on neuromuscular/CNS indications and targeted delivery of nucleic acid payloads, although using antibody-based rather than aptamer-based targeting.

TypeBroad incumbent
Description

Alnylam is the leading siRNA therapeutics company with multiple approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) and an extensive clinical pipeline across rare and common diseases. Broad incumbent that anchors the RNA therapeutics category in which Creyon competes.

TypeBroad incumbent
Description

Ionis invented antisense oligonucleotide (ASO) therapeutics and commercializes multiple approved products (Spinraza, Tegsedi, Waylivra, Wainua). Broad incumbent with deep CNS and rare disease programs that overlaps directly with Creyon's splice-switching ASO and CNS delivery ambitions.

TypeDirect peer
Description

Arrowhead develops RNAi-based therapeutics with its TRiM targeting platform that enables extra-hepatic and tissue-directed delivery of siRNA. Direct peer in targeted nucleic acid delivery with multiple clinical-stage programs across liver, muscle, lung, and CNS.

TypeDirect peer
Description

Wave develops stereopure oligonucleotide therapeutics including siRNA and antibody-oligonucleotide conjugate programs for CNS and rare diseases such as HD, ALS, and DMD. Direct peer with shared RNA chemistry platform emphasis and CNS focus area.

TypeEmerging player
Description

Entrada develops intracellular enzyme-based delivery technology for oligonucleotide and protein therapeutics in rare diseases including DM1 and DMD. Emerging player with comparable rare neuromuscular focus and distinctive delivery innovation.

TypeDirect peer
Description

Stoke develops antisense oligonucleotide medicines that increase functional protein production via RNA splice modulation for severe genetic diseases (e.g., ADOA, Dravet). Direct peer given highly analogous splice-switching ASO therapeutic approach.

TypeEmerging player
Description

ProQR develops Axiomer RNA editing therapeutics (siRNA-conjugate based) and other oligonucleotide treatments for rare diseases such as Rett syndrome. Emerging player with adjacent oligonucleotide platform technology addressing rare genetic diseases.

TypeOthers
Description

Genevant is a lipid nanoparticle (LNP) delivery platform company developing RNAi and mRNA therapeutics. Thematically adjacent peer given Creyon's stated LNP-targeting capability and shared focus on nucleic acid delivery innovation, though they do not directly compete in the same aptamer-based delivery niche.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Creyon Bio

RNA-based Drug Developmentcreyonbio.com

Creyon Bio is a private drug development company engineering oligonucleotide-based medicines (OBMs) using aptamer delivery technology and its AI-powered NuclelQ platform for immunology, CNS, and neuromuscular diseases, generating revenue through pharmaceutical partnerships.

What Creyon Bio does

Creyon Bio is a privately held drug development company engineering oligonucleotide-based medicines (OBMs) for immunology, central nervous system (CNS), and neuromuscular diseases. The company combines two proprietary technology pillars: an aptamer-based delivery platform—anchored by a transferrin receptor (TfR) aptamer with validated preclinical proof-of-concept for crossing the blood-brain barrier—and the NuclelQ™ AI-powered nucleic acid engineering platform, which leverages proprietary pharmacology datasets and AI/ML predictive tools to design safe and active nucleic acid candidates. Creyon has three active wholly-owned programs, including a first-in-class splice-switching oligonucleotide therapy for late-onset Pompe disease and a CNS program enabled by BBB-crossing delivery; the platform is also being extended to direct lipid nanoparticles (LNPs) to immune and other cell types beyond oligonucleotides.

The company operates a licensing and partnership-driven business model rather than selling products directly. Revenue mechanics consist of upfront payments, development milestones, and royalties on partnered programs, anchored by a strategic partnership with Eli Lilly announced in 2025 valued at up to $1 billion for oligonucleotide therapeutics. Creyon is headquartered in San Diego, California with research operations in Research Triangle Park, North Carolina, and was launched in March 2022 with over $40 million in combined Seed and Series A funding co-led by DCVC Bio and Lux Capital. Customer base consists of large pharmaceutical partners rather than end patients or providers, with Eli Lilly named as the primary disclosed enterprise customer.

Creyon Bio firmographics

Firmographics
Name
Creyon Bio
Legal name
Creyon Bio
Website
https://creyonbio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Creyon Bio is a private drug development company engineering oligonucleotide-based medicines (OBMs) using aptamer delivery technology and its AI-powered NuclelQ platform for immunology, CNS, and neuromuscular diseases, generating revenue through pharmaceutical partnerships.
Ownership category
akta.pro rank

Where Creyon Bio is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Creyon Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. RNA-based Drug Development & Licensing: Creyon Bio is developing RNA-based medicines (OBMs) for treatment of immunology, CNS, and neuromuscular diseases. Revenue generation through licensing deals and eventual product commercialization for common and rare diseases.
  2. Strategic Partnership Deals: Revenue through pharmaceutical partnerships such as the up to $1 billion deal with Eli Lilly for oligonucleotide therapeutics development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Creyon Bio product offering

Product offering

Core offering

Creyon Bio is a drug development company engineering RNA-based medicines (Oligonucleotide-Based Medicines, or OBMs) for immunology, central nervous system (CNS), and neuromuscular diseases. Its approach combines the NuclelQ™ AI-powered nucleic acid engineering platform with proprietary aptamer-based delivery technology that targets specific cell types and can cross the blood-brain barrier, enabling tissue-specific delivery of siRNA and antisense oligonucleotides.

Product overview

Creyon Bio is a drug development company offering a platform-plus-technology approach to RNA-based medicine design. The core offering is the NuclelQ™ AI-Powered Nucleic Acid Engineering Platform, which uses proprietary pharmacology datasets and machine learning to design nucleic acid therapies. This platform is combined with the company's Aptamer Delivery Technology for cell-specific targeting, including the Transferrin Receptor (TfR) Aptamer for blood-brain barrier crossing. The company engineers Oligonucleotide-Based Medicines (OBMs) as precision drugs for immunology, CNS, and neuromuscular diseases. Creyon has three active wholly-owned products in its pipeline, including a late-onset Pompe disease therapy and a CNS program. The platform can direct both aptamers and lipid nanoparticles (LNPs) to immune and other cell types.

Differentiator

Problem solved

Functional benefit

Brands

  • NuclelQ™: AI-Powered Nucleic Acid Engineering Platform that enables de-risked design of safe and active nucleic acid therapies using proprietary pharmacology datasets and AI/ML predictive tools.

Products and services

  • Late-Onset Pompe Disease Therapy First-in-class splice-switching oligonucleotide therapy leveraging the TfR aptamer for targeted muscle delivery in late-onset Pompe disease; intended to restore endogenous acid alpha-glucosidase (GAA) production and sustain glycogen reduction. Developed by Creyon Bio as a wholly-owned drug candidate for partnership-based clinical advancement.
  • CNS Program (TfR Aptamer-Mediated Delivery) Wholly-owned CNS pipeline program using the transferrin receptor (TfR) aptamer to shuttle siRNA and antisense oligonucleotides across the blood-brain barrier to disease-relevant targets in the brain. Preclinical proof-of-concept demonstrated; intended to support a broad set of CNS indications.
  • Immunology Program (T and B Cell-Targeted OBMs) Wholly-owned immunology pipeline of OBMs designed for precise delivery of therapeutic payloads to T and B cells using proprietary aptamers, intended to modulate immune pathways and treat immune-driven diseases.

Companies that use Creyon Bio

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Creyon Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Creyon Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli LillycoreStrategic or Co-development Partner · 1 January 2025Eli Lilly partnership for oligonucleotide therapeutics worth up to $1 billion, including development milestones and royalties. Part of Lilly's broader AI-driven pharmaceutical strategy combining high-stakes discovery partnerships with pragmatic operational AI deployment. Creyon Bio contributes differentiated RNA drug design capabilities using its aptamer delivery platform and NuclelQ AI technology.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Creyon Bio competitors and assessment

Company assessment

Direct peers

  • Dyne Therapeutics: Dyne develops targeted oligonucleotide therapies (siRNA, ASO) for serious muscle diseases (DM1, DMD, FSHD, Pompe) using its FORCE antibody fragment-targeted platform. Direct peer given shared focus on muscle-targeted nucleic acid delivery and overlap in Pompe disease, though Dyne uses antibody fragments rather than aptamer-based targeting.
  • Avidity Biosciences: Avidity develops antibody-oligonucleotide conjugates (AOCs) for muscle and CNS diseases including DM1, DMD, FSHD, and rare metabolic disorders. Direct peer due to nearly identical therapeutic-area focus on neuromuscular/CNS indications and targeted delivery of nucleic acid payloads, although using antibody-based rather than aptamer-based targeting.
  • Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics with its TRiM targeting platform that enables extra-hepatic and tissue-directed delivery of siRNA. Direct peer in targeted nucleic acid delivery with multiple clinical-stage programs across liver, muscle, lung, and CNS.
  • Wave Life Sciences: Wave develops stereopure oligonucleotide therapeutics including siRNA and antibody-oligonucleotide conjugate programs for CNS and rare diseases such as HD, ALS, and DMD. Direct peer with shared RNA chemistry platform emphasis and CNS focus area.
  • Stoke Therapeutics: Stoke develops antisense oligonucleotide medicines that increase functional protein production via RNA splice modulation for severe genetic diseases (e.g., ADOA, Dravet). Direct peer given highly analogous splice-switching ASO therapeutic approach.

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the leading siRNA therapeutics company with multiple approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) and an extensive clinical pipeline across rare and common diseases. Broad incumbent that anchors the RNA therapeutics category in which Creyon competes.
  • Ionis Pharmaceuticals: Ionis invented antisense oligonucleotide (ASO) therapeutics and commercializes multiple approved products (Spinraza, Tegsedi, Waylivra, Wainua). Broad incumbent with deep CNS and rare disease programs that overlaps directly with Creyon's splice-switching ASO and CNS delivery ambitions.

Emerging players

  • Entrada Therapeutics: Entrada develops intracellular enzyme-based delivery technology for oligonucleotide and protein therapeutics in rare diseases including DM1 and DMD. Emerging player with comparable rare neuromuscular focus and distinctive delivery innovation.
  • ProQR Therapeutics: ProQR develops Axiomer RNA editing therapeutics (siRNA-conjugate based) and other oligonucleotide treatments for rare diseases such as Rett syndrome. Emerging player with adjacent oligonucleotide platform technology addressing rare genetic diseases.

Others

  • Genevant Sciences: Genevant is a lipid nanoparticle (LNP) delivery platform company developing RNAi and mRNA therapeutics. Thematically adjacent peer given Creyon's stated LNP-targeting capability and shared focus on nucleic acid delivery innovation, though they do not directly compete in the same aptamer-based delivery niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Creyon Bio social profiles

Digital presence

Creyon Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Creyon Bio leadership team

Management profile

Number of profiles

Profiles5 records

Creyon Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Creyon Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Creyon Bio

What does Creyon Bio do?

Creyon Bio is a drug development company engineering RNA-based medicines (Oligonucleotide-Based Medicines, or OBMs) for immunology, central nervous system (CNS), and neuromuscular diseases. Its approach combines the NuclelQ™ AI-powered nucleic acid engineering platform with proprietary aptamer-based delivery technology that targets specific cell types and can cross the blood-brain barrier, enabling tissue-specific delivery of siRNA and antisense oligonucleotides.

Is Creyon Bio a public or private company?

Creyon Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Creyon Bio founded?

Creyon Bio was founded in 2022. It employs 11 to 50 people.

Where is Creyon Bio based?

Creyon Bio is headquartered in San Diego, United States, in the North America region.

How does Creyon Bio make money?

Two revenue lines are on record. RNA-based Drug Development & Licensing is the primary driver. The others are strategic Partnership Deals.

Who are Creyon Bio's main competitors?

Direct peers on record are Dyne Therapeutics, Avidity Biosciences, Arrowhead Pharmaceuticals, Wave Life Sciences and Stoke Therapeutics. Broad incumbents are Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Emerging players are Entrada Therapeutics and ProQR Therapeutics. Genevant Sciences is listed as an others.

Does Creyon Bio have an API?

No public API is recorded for Creyon Bio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldWith new leadership, Creyon enters a $1B-plus deal with LillyPrivately held Creyon Bio Inc. has entered a licensing and research partnership with Eli Lilly and Co. to develop RNA-targeted oligonucleotide treatments for various diseases. Under the agreement, Creyon receives an upfront payment of $13 million and is eligible for over $1 billion in potential milestone payments.AxiosCreyon Bio and Eli Lilly sign licensing deal worth $1 billionCreyon Bio, a San Diego biotech developing nucleic acid drugs, signed a licensing and multi-target research deal with Eli Lilly worth up to $1 billion. The agreement comes as Creyon seeks $15 million to $20 million in Series A extension funding. This partnership provides Creyon with substantial non-dilutive capital while granting Eli Lilly access to Creyon's nucleic acid drug technology platform.GlobeNewswireCreyon Bio Appoints Venture Capitalists Serge Messerlian and Shaquille Vayda to Board of DirectorsCreyon Bio appointed Serge Messerlian and Shaquille Vayda to its board of directors. Messerlian is Operating Partner at DCVC Bio, and Vayda is Principal at Lux Capital. The appointments aim to support Creyon's AI-enabled engineering of oligonucleotide-based medicines.PR NewswireDavid Dimmock, M.D., Joins Creyon Bio as Chief Medical OfficerCreyon Bio, a pre-clinical stage drug development company specializing in RNA-based oligonucleotide medicines, announced the appointment of David Dimmock, M.D. as Chief Medical Officer. Dr. Dimmock previously spent six years at Rady Children's Institute for Genomic Medicine leading rapid precision medicine implementation using whole genome sequencing. He will lead the development of pre-clinical and clinical data for Creyon Bio's machine learning-driven platform designed to engineer safe and effective oligonucleotide-based medicines.trib.alCreyon Bio gets some green for a new take on AI and genetic meds R&DCreyon Bio, a San Diego and Research Triangle Park-based startup, raised $40 million in seed and Series A funding to advance AI-based oligonucleotide drug discovery. The company aims to produce safety and toxicity data without animal testing, potentially enabling therapies for common diseases beyond rare ones.socaltech.comCreyon Bio Gets $40M For Precision MedicineCreyon Bio raised $40M in a funding round led by DCVC Bio and Lux Capital, with participation from Casdin Capital, Alexandria Venture Investments, and BioBrit. The funds will support its drug development platform for oligonucleotide-based medicines and expand its team.BioSpaceCreyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All PatientsCreyon Bio launched its RNA-based medicine platform, aiming to engineer precision medicines on demand for patients of all sizes. The company secured over $40 million in seed and Series A financing led by DCVC Bio and Lux Capital. The platform uses machine learning and purpose-built datasets to design oligonucleotide-based medicines efficiently.PR NewswireCreyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All PatientsCreyon Bio, Inc. launched on March 8, 2022, as a drug development company focused on engineering RNA-based oligonucleotide-based medicines (OBMs) with predictable safety and efficacy profiles using machine learning and purpose-built datasets. The company has secured over $40 million in seed and Series A financing co-led by DCVC Bio and Lux Capital, with additional participation from Casdin Capital, Alexandria Venture Investments, and BioBrit. The funding will support continued optimization of the Creyon Platform, team expansion, and development of an internal pipeline targeting both rare and common diseases.Trust & Safety PoliciesCreyon Bio is Creating Precision Medicines for Diseases Common and RareCreyon Bio, a San Diego and North Carolina-based drug development company, has launched with over $40 million in seed and Series A financing led by DCVC Bio and Lux Capital. The company utilizes machine learning to engineer oligonucleotide-based medicines (OBMs) for both common and rare diseases, aiming to improve the efficiency of drug discovery. This platform approach seeks to reduce the time and cost associated with traditional trial-and-error screening methods.FinSMEsCreyon Bio Secures $40M in Seed and Series A FinancingCreyon Bio secured $40 million in combined Seed and Series A financing led by DCVC Bio and Lux Capital. The company intends to utilize these funds to optimize its proprietary platform for engineering RNA-based medicines and expand its team.